In PLK2-/- triple-negative breast cancer patient-derived xenograft (PDX) mice model, re-expression of PLK2 significantly reduces the therapeutic effect of PLK1 inhibitor Volasertib (110). Here, PLK2 is linked to triple-negative breast carcinoma.